• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症耐药的分子机制：新兴生物标志物及克服肿瘤进展的潜在靶点

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression.

作者信息

Fontana Fabrizio, Anselmi Martina, Limonta Patrizia

机构信息

Department of Pharmacological and Biomolecular Sciences, University of Milano, 20133 Milano, Italy.

出版信息

Cancers (Basel). 2022 Mar 23;14(7):1614. doi: 10.3390/cancers14071614.

DOI:10.3390/cancers14071614
PMID:35406386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8997078/
Abstract

Cancer still represents a major global burden, being the second leading cause of death worldwide [...].

摘要

癌症仍然是一个重大的全球负担，是全球第二大死因[……]。

相似文献

1
Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression.癌症耐药的分子机制：新兴生物标志物及克服肿瘤进展的潜在靶点
Cancers (Basel). 2022 Mar 23;14(7):1614. doi: 10.3390/cancers14071614.
2
Molecular mechanisms of chemoresistance in gastric cancer.胃癌化疗耐药的分子机制
World J Gastrointest Oncol. 2016 Sep 15;8(9):673-81. doi: 10.4251/wjgo.v8.i9.673.
3
MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer.微小 RNA：肺癌中的新兴致癌和抑癌调节因子、生物标志物和治疗靶点。
Cancer Lett. 2021 Apr 1;502:71-83. doi: 10.1016/j.canlet.2020.12.040. Epub 2021 Jan 13.
4
Modulating undruggable targets to overcome cancer therapy resistance.调节不可成药靶点以克服癌症治疗耐药性。
Drug Resist Updat. 2022 Jan;60:100788. doi: 10.1016/j.drup.2021.100788. Epub 2021 Dec 3.
5
Emerging treatment for advanced lung cancer with EGFR mutation.针对具有表皮生长因子受体（EGFR）突变的晚期肺癌的新兴治疗方法。
Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8.
6
Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives.循环微RNA作为胃癌潜在的诊断生物标志物和治疗靶点：现状与未来展望
Curr Med Chem. 2016;23(36):4135-4150. doi: 10.2174/0929867323666160818093854.
7
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes.新型策略应对人类病原微生物新兴耐药性。
Curr Drug Targets. 2021;22(12):1424-1436. doi: 10.2174/1389450121666201228123212.
8
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.基于免疫检查点抑制剂的癌症免疫治疗耐药性：靶点、生物标志物和治疗方法。
Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15.
9
Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer.微小RNA在肺癌表皮生长因子受体靶向治疗中的新作用
Biomed Res Int. 2015;2015:672759. doi: 10.1155/2015/672759. Epub 2015 Jul 26.
10
The Emerging Role of Extracellular Vesicles in Endocrine Resistant Breast Cancer.细胞外囊泡在内分泌抵抗性乳腺癌中的新兴作用
Cancers (Basel). 2021 Mar 8;13(5):1160. doi: 10.3390/cancers13051160.

引用本文的文献

1
Redefining Chemoresistance: Natural Bioactives as Molecular Modulators at the Cancer-Tumor Microenvironment Interface.重新定义化疗耐药性：天然生物活性物质作为癌症-肿瘤微环境界面的分子调节剂
Int J Mol Sci. 2025 Aug 20;26(16):8037. doi: 10.3390/ijms26168037.
2
NAC1/ACOX2 Axis as a Novel Therapeutic Target for Endometriosis-Related Ovarian Neoplasms.NAC1/ACOX2轴作为子宫内膜异位症相关卵巢肿瘤的新型治疗靶点
Int J Mol Sci. 2025 May 21;26(10):4938. doi: 10.3390/ijms26104938.
3
Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.基于水凝胶的纳米颗粒：革新脑肿瘤治疗并为未来创新铺平道路。
Eur J Med Res. 2025 Feb 4;30(1):71. doi: 10.1186/s40001-025-02310-2.
4
A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer.基于纳米材料的天然光敏剂克服癌症多药耐药性的疗效综述
Pharmaceutics. 2024 Aug 24;16(9):1120. doi: 10.3390/pharmaceutics16091120.
5
Acyl Urea Compounds Therapeutics and its Inhibition for Cancers in Women: A Review.酰基脲化合物疗法及其对女性癌症的抑制作用：综述
Anticancer Agents Med Chem. 2025;25(2):86-98. doi: 10.2174/0118715206330232240913100744.
6
The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target.鞘氨醇-1-磷酸和鞘氨醇激酶1在癌症耐药中的新作用：一个有前景的治疗靶点。
Cancer Cell Int. 2024 Feb 28;24(1):89. doi: 10.1186/s12935-024-03221-8.
7
Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.当代小儿横纹肌肉瘤临床前小鼠模型：从床边到实验台再回到床边
Front Oncol. 2024 Feb 2;14:1333129. doi: 10.3389/fonc.2024.1333129. eCollection 2024.
8
How gallic acid regulates molecular signaling: role in cancer drug resistance.没食子酸如何调节分子信号转导：在癌症药物耐药中的作用。
Med Oncol. 2023 Sep 27;40(11):308. doi: 10.1007/s12032-023-02178-4.
9
Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.靶向肿瘤微环境以克服耐药性的治疗药物纳米制剂的当前进展。
Cancer Metastasis Rev. 2023 Sep;42(3):959-1020. doi: 10.1007/s10555-023-10119-w. Epub 2023 Jul 28.
10
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.外泌体非编码RNA在乳腺癌耐药中的研究概况，重点关注潜在分子机制。
Front Pharmacol. 2023 Apr 19;14:1152672. doi: 10.3389/fphar.2023.1152672. eCollection 2023.

本文引用的文献

1
Systemic Mobilization of Breast Cancer Resistance Protein in Response to Oncogenic Stress.响应致癌应激时乳腺癌耐药蛋白的全身动员
Cancers (Basel). 2022 Jan 9;14(2):313. doi: 10.3390/cancers14020313.
2
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
4
Microbiome in drug resistance to colon cancer.微生物群与结肠癌耐药性
Curr Opin Physiol. 2021 Oct;23. doi: 10.1016/j.cophys.2021.100472. Epub 2021 Aug 17.
5
Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay.乳腺癌耐药性：通过利用微小RNA与肿瘤微环境的相互作用来克服这一挑战
Cancers (Basel). 2021 Jul 22;13(15):3691. doi: 10.3390/cancers13153691.
6
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.骨肉瘤中的耐药性：新兴生物标志物、治疗靶点与治疗策略
Cancers (Basel). 2021 Jun 9;13(12):2878. doi: 10.3390/cancers13122878.
7
MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer.微小RNA作为前列腺癌治疗反应的表观遗传决定因素及潜在治疗靶点
Cancers (Basel). 2021 May 14;13(10):2380. doi: 10.3390/cancers13102380.
8
Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing in Colorectal Cancer.肠道微生物群作为改善癌症管理的潜在生物标志物和/或治疗靶点：聚焦于结直肠癌中产生大肠杆菌素的情况
Cancers (Basel). 2021 May 5;13(9):2215. doi: 10.3390/cancers13092215.
9
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.靶向癌症治疗中的小分子：进展、挑战和未来展望。
Signal Transduct Target Ther. 2021 May 31;6(1):201. doi: 10.1038/s41392-021-00572-w.
10
Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in -Mutant Melanoma Cell Lines.抑制心肌素相关转录因子途径可提高曲美替尼在BRAF突变黑色素瘤细胞系中的疗效。
Cancers (Basel). 2021 Apr 22;13(9):2012. doi: 10.3390/cancers13092012.